{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T02:07:56Z","timestamp":1783822076488,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Although the guidelines recommend gynecological assessment and close monitoring for symptoms of endometrial cancer in postmenopausal breast cancer survivors taking tamoxifen (TAM), the risk of endometrial cancer in young breast cancer survivors has not yet been fully assessed. This study aimed to investigate the risk of developing endometrial cancer and the frequencies of gynecological examinations in young breast cancer survivors taking TAM in South Korea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A nationwide retrospective cohort study was conducted using the Health Insurance Review and Assessment Service claims data. Kaplan\u2013Meier analyses and log-rank tests were used to assess the probability of endometrial cancer, benign endometrial conditions, and the probability of invasive endometrial procedure. To analyze the risk of endometrial cancer and benign endometrial conditions, we used a multivariable Cox proportional hazards regression model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between 2010 and 2015, 60,545 newly diagnosed female breast cancer survivors were included. The total person\u2013years were 256,099 and 140 (0.23%) patients developed endometrial cancer during the study period. In breast cancer survivors aged \u226560 years [hazard ratio (HR), 5.037; 95% confidence interval (CI), 2.185\u201311.613], 50\u201359 years (HR, 4.343; 95% CI, 2.122\u20138.891), and 40\u201349 years (HR, 2.121; 95% CI, 1.068\u20134.213), TAM was associated with an increased risk of endometrial cancer. In subjects aged below 40 years, TAM did not significantly increase the risk of endometrial cancer. However, among the TAM subgroups, breast cancer survivors aged below 40 years [1.61 per 1,000 person\u2013years (PY); HR, 12.460; 95% CI, 2.698\u201357.522] and aged 40\u201349 years (2.22 per 1,000 PY; HR, 9.667; 95% CI, 4.966\u201318.819) with TAM-related endometrial diseases showed significantly increased risks of endometrial cancer. Among the TAM subgroup with benign endometrial conditions, the ratios of the frequency of invasive diagnostic procedures to the incidence of endometrial cancer were higher in subjects under 40 than subjects aged 60 or more.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Young breast cancer survivors with TAM-related benign endometrial diseases are at a higher risk of developing endometrial cancer. Gynecological surveillance should be tailored to the risk of endometrial cancer in young breast cancer survivors to improve the early detection of endometrial cancer and avoid unnecessary invasive procedures.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.636378","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T18:26:06Z","timestamp":1622744766000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Soojeong","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Ho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhong","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Seok","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Ho","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei Hyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yura","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il Yong","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (Nsabp) B-14","volume":"86","author":"Fisher","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.2258","article-title":"Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update","volume":"32","author":"Burstein","year":"2014","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1023\/B:BREA.0000021050.92539.b0","article-title":"Association of Tamoxifen (TAM) and TAM Metabolite Concentrations With Self-Reported Side Effects of TAM in Women With Breast Cancer","volume":"85","author":"Gallicchio","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jncimonographs.a003450","article-title":"Impact of Tamoxifen Adjuvant Therapy on Symptoms, Functioning, and Quality of Life","volume":"2001","author":"Ganz","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-13-0389","article-title":"Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings","volume":"7","author":"Chlebowski","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"R91","DOI":"10.1186\/bcr3206","article-title":"Endometrial Cancer Survival After Breast Cancer in Relation to Tamoxifen Treatment: Pooled Results From Three Countries","volume":"14","author":"Jones","year":"2012","journal-title":"Breast Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1999.5519","article-title":"Tamoxifen and Endometrial Pathologies: A Prospective Study","volume":"75","author":"Seoud","year":"1999","journal-title":"Gynecol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji057","article-title":"Tamoxifen Treatment for Breast Cancer and Risk of Endometrial Cancer: A Case-Control Study","volume":"97","author":"Swerdlow","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000450757.18294.cf","article-title":"No. 601: Tamoxifen and Uterine Cancer","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.3809","article-title":"American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline","volume":"34","author":"Runowicz","year":"2016","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2017.32.5.718","article-title":"Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data","volume":"32","author":"Kim","year":"2017","journal-title":"J Korean Med Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e276","article-title":"Nationwide Analysis of Treatment Patterns for Korean Breast Cancer Survivors Using National Health Insurance Service Data","volume":"33","author":"Chung","year":"2018","journal-title":"J Korean Med Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz173","article-title":"Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up\u2020","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00002018-200022010-00001","article-title":"Guidelines for Monitoring Patients Taking Tamoxifen Treatment","volume":"22","author":"Neven","year":"2000","journal-title":"Drug Saf"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200209000-00012","article-title":"Controversy About Uterine Effects and Safety of SERMs: The Saga Continues","volume":"9","author":"Goldstein","year":"2002","journal-title":"Menopause"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.20.3459","article-title":"Effect of Adjuvant Tamoxifen on the Endometrium in Women With Breast Cancer: A Prospective Study Using Office Endometrial Biopsy","volume":"18","author":"Barakat","year":"2000","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.20.3464","article-title":"Effects of Adjuvant Tamoxifen on the Endometrium in Postmenopausal Women With Breast Cancer: A Prospective Long-Term Study Using Transvaginal Ultrasound","volume":"18","author":"Gerber","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4103\/tcmj.tcmj_17_19","article-title":"Younger Tamoxifen-Treated Breast Cancer Patients Also had Higher Risk of Endometrial Cancer and the Risk Could be Reduced by Sequenced Aromatase Inhibitor Use: A Population-Based Study in Taiwan","volume":"32","author":"Chu","year":"2020","journal-title":"Ci Ji Yi Xue Za Zhi"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years Versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor-Positive Breast Cancer: ATLAS, a Randomised Trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.18_suppl.5","article-title":"Attom: Long-term Effects of Continuing Adjuvant Tamoxifen to 10 Years Versus Stopping at 5 Years in 6,953 Women With Early Breast Cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10899","article-title":"Meta-Analysis of the Cumulative Risk of Endometrial Malignancy and Systematic Review of Endometrial Surveillance in Extended Tamoxifen Therapy","volume":"105","author":"Fleming","year":"2018","journal-title":"Br J Surg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia","volume":"37","author":"DeCensi","year":"2019","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e13976","DOI":"10.1097\/MD.0000000000013976","article-title":"Event-Free Survival Following Early Endometrial Events in Breast Cancer Patients Treated With Anti-Hormonal Therapy: A Nationwide Claims Data Study","volume":"98","author":"Lee","year":"2019","journal-title":"Med (Baltimore)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.636378\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T18:26:09Z","timestamp":1622744769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.636378\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":25,"alternative-id":["10.3389\/fonc.2021.636378"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.636378","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"article-number":"636378"}}